EA201001640A1 - PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHOD - Google Patents

PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHOD

Info

Publication number
EA201001640A1
EA201001640A1 EA201001640A EA201001640A EA201001640A1 EA 201001640 A1 EA201001640 A1 EA 201001640A1 EA 201001640 A EA201001640 A EA 201001640A EA 201001640 A EA201001640 A EA 201001640A EA 201001640 A1 EA201001640 A1 EA 201001640A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutically acceptable
nanoparticles
forms
acceptable carrier
antibiotic
Prior art date
Application number
EA201001640A
Other languages
Russian (ru)
Other versions
EA016410B1 (en
Inventor
Светлана Эммануиловна ГЕЛЬПЕРИНА
Ольга Олеговна МАКСИМЕНКО
Людмила Витальевна ВАНЧУГОВА
Елена Владимировна ШИПУЛО
Владимир Евстахиевич БАБИЙ
Алексей Владимирович ИГНАТЬЕВ
Original Assignee
Ооо "Нпк Наносистема"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Нпк Наносистема" filed Critical Ооо "Нпк Наносистема"
Priority to EA201001640A priority Critical patent/EA016410B1/en
Publication of EA201001640A1 publication Critical patent/EA201001640A1/en
Publication of EA016410B1 publication Critical patent/EA016410B1/en

Links

Abstract

Изобретение относится к медицине и фармации, а именно к фармацевтической композиции для лечения микобактериозов и геликобактерной инфекции, на основе диспергированных в фармацевтически приемлемом носителе наночастиц циклодекстрина размером от 100 до 1000 нм, содержащих терапевтически эффективное количество диспергированного в них антибиотика из группы рифамицинов (предпочтительно рифабутина), а также фармацевтически приемлемые вспомогательные вещества, отличающейся тем, что указанные наночастицы не содержат полимера, к способу получения (синтеза) указанной фармацевтической композиции, а также к способам лечения микобактериозов и геликобактерной инфекции, включающим внутривенное, и/или внутримышечное, и/или пероральное введение нуждающемуся в этом пациенту указанной композиции (в виде суспензии в фармацевтически приемлемом носителе) в терапевтически эффективном количестве. Композиция в соответствии с изобретением может быть выполнена как в виде лиофилизата, пригодного (после диспергирования в фармацевтически приемлемом носителе) для внутривенного или внутримышечного введения пациенту, так и в виде порошка, пригодного для изготовления твердых пероральных лекарственных форм, и обеспечивает эффективность не менее (а в ряде случаев - и более) высокую, чем традиционные пероральные формы рифабутина (капсулы), и лишена недостатков как существующих традиционных пероральных форм, так и известных наносомальных (коллоидных) форм данного антибиотика.The invention relates to medicine and pharmacy, in particular to a pharmaceutical composition for the treatment of mycobacteriosis and helicobacter infection, based on cyclodextrin nanoparticles from 100 to 1000 nm dispersed in a pharmaceutically acceptable carrier, containing a therapeutically effective amount of a rifamycin (preferably rifabutin) antibiotic dispersed in them as well as pharmaceutically acceptable excipients, characterized in that the said nanoparticles do not contain a polymer, to the method of obtaining (synthesis) of the specified pharmaceutical composition, as well as to methods for treating mycobacteriosis and helicobacter infection, including intravenous and / or intramuscular and / or oral administration to the patient in need of the specified composition (as a suspension in a pharmaceutically acceptable carrier) in a therapeutically effective amount . The composition in accordance with the invention can be performed both as a lyophilisate, suitable (after dispersing in a pharmaceutically acceptable carrier) for intravenous or intramuscular administration to a patient, or as a powder suitable for making solid oral dosage forms, and provides efficacy no less ( in some cases - and more) higher than traditional oral forms of rifabutin (capsules), and is free from the drawbacks of both existing traditional oral forms and known nanosomal ( loidnyh) forms of the antibiotic.

EA201001640A 2010-11-13 2010-11-13 Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants) EA016410B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201001640A EA016410B1 (en) 2010-11-13 2010-11-13 Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201001640A EA016410B1 (en) 2010-11-13 2010-11-13 Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants)

Publications (2)

Publication Number Publication Date
EA201001640A1 true EA201001640A1 (en) 2012-03-30
EA016410B1 EA016410B1 (en) 2012-04-30

Family

ID=45908240

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001640A EA016410B1 (en) 2010-11-13 2010-11-13 Pharmaceutical composition based on cyclodextrin nanoparticles comprising rifabutin, method for preparing thereof, method for treating mikobacteriosis and helicobacterial infection (variants)

Country Status (1)

Country Link
EA (1) EA016410B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015519A (en) * 2019-09-12 2021-06-22 生物验证系统股份公司 Rifabutin treatment methods, uses and compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344537B2 (en) 2019-09-18 2022-05-31 BioVersys AG Rifabutin treatment methods, uses, and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149030A0 (en) * 2000-08-09 2002-11-10 Panacea Biotec Ltd Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof
ES2310122B1 (en) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A NANOPARTICLES THAT INCLUDE A CYCLODEXTRINE AND A BIOLOGICALLY ACTIVE MOLECULA AND ITS APPLICATIONS.
EA200801388A1 (en) * 2008-06-20 2009-08-28 Ооо «Нпк "Наносистема"» PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS AND DISEASES MEDIATED BY HELICOBACTER PILORY BASED ON POLYMERIC NANOPARTICLES, ITS TREATMENT METHOD AND TREATMENT METHOD

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015519A (en) * 2019-09-12 2021-06-22 生物验证系统股份公司 Rifabutin treatment methods, uses and compositions

Also Published As

Publication number Publication date
EA016410B1 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
RU2010140682A (en) METHOD FOR TREATING PATIENTS FROM INFECTION, PHARMACEUTICAL COMPOSITION (OPTIONS) AND MEDICINE
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201590836A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL COATING
EA201690069A1 (en) THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
RU2013148732A (en) COMBINATIONS OF COMPOUNDS INHIBITING ACT AND CHEMOTHERAPEUTIC AGENTS AND WAYS OF THEIR APPLICATION
WO2012007159A3 (en) Novel gastro-retentive dosage forms
RU2013156378A (en) 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for use in the treatment of adenocystic carcinoma
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2010132581A (en) METHODS FOR LUNG DISEASES THERAPY
RU2013127420A (en) WAYS TO REDUCE PSYCHOGENIC OR COMPULSIVE Overeating
MX2022012351A (en) Co-administration of mirdametinib and lifirafenib for use in treating cancers.
RU2017113354A (en) INJECTION MICROPARTICLES FOR SUPERLOCALIZED RELEASE OF THERAPEUTIC MEDICINES
HRP20210418T1 (en) Syd985 treatment of t-dm1 refractory cancer patients
JP2016512247A5 (en)
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
RU2012108144A (en) ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES
EA201001640A1 (en) PHARMACEUTICAL ANTIBACTERIAL COMPOSITION BASED ON NANOPARTICLES CYCLODEXTRIN CONTAINING ANTIBIOTIC FROM RIFAMYCIN GROUP, METHOD FOR ITS PRODUCTION AND METHOD
JP2010106019A (en) Agent of prophylaxis, therapy, and or symptom alleviation for peripheral neuropathy resulting from cancer chemotherapy comprising limaprost
RU2013105513A (en) Derivatives of 1-aminoalkylcyclohexane for the treatment of inflammatory skin diseases
EA200900214A1 (en) PHARMACEUTICAL COMPOSITION OF RIFABUTIN FOR THE TREATMENT OF TUBERCULOSIS, THE WAY OF ITS OBTAINING AND THE METHOD OF TREATMENT
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
WO2022021786A1 (en) Tsl-1502 compound pharmaceutical composition

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU

PC4A Registration of transfer of a eurasian patent by assignment